甲氨蝶呤联合桥接糖皮质激素伴或不伴早期引入6个月依那西普疗程在早期类风湿关节炎中的有效性:为期2年的实用性随机CareRA2020试验结果
CareRA2020是一项为期2年的开放性多中心实用性随机对照试验,纳入未经治疗早期类风湿关节炎患者,起始甲氨蝶呤联合糖皮质激素桥接(COBRA-Slim方案),早期应答不足者随机接受标准方案(先加来氟米特)或生物诱导方案(加依那西普24周)。生物诱导方案在104周DAS28-CRP主要结局上未显示优效,但随机化后28周DAS28-CRP<2.6达标率更高,第104周使用b/tsDMARDs者更少。
要点
- 早期应答不足者中,加用依那西普6个月在104周疾病控制上未优于先加来氟米特。
- 生物诱导组随机化后28周DAS28-CRP<2.6达标率59%,标准组44%。
- 第104周生物诱导组19/55(35%)使用b/tsDMARDs,标准组29/55(53%)。
核心结论
- 在早期应答不足的早期类风湿关节炎患者中,加用依那西普6个月在104周疾病控制上未优于先加来氟米特。
- 但暂时引入依那西普使随机化后早期疾病控制改善,且第104周使用b/tsDMARDs的患者更少。
研究设计与样本
- CareRA2020(NCT03649061)是一项为期2年的开放性多中心实用性随机对照试验。
- 未经治疗患者起始甲氨蝶呤联合糖皮质激素桥接(COBRA-Slim方案)。
- 在第8周至第32周时间窗内,早期应答不足者被随机分配至标准-CS策略(先加来氟米特)或生物诱导-CS策略(加依那西普24周)。
主要发现
- COBRA-Slim治疗后142例为早期应答者,55例早期应答不足者接受标准-CS,55例接受生物诱导-CS。
- 主要结局(104周DAS28-CRP纵向变化)未证明生物诱导-CS优于标准-CS(ß=-0.204,95%CI -0.486至0.078,p=0.157)。
- 随机化后28周DAS28-CRP<2.6达标率:生物诱导-CS组59%(95%CI 44%至72%),标准-CS组44%(95%CI 31%至59%)。
- 第104周使用b/tsDMARDs:生物诱导-CS组19/55(35%),标准-CS组29/55(53%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate if patients with early rheumatoid arthritis responding insufficiently to initial methotrexate (MTX) and bridging glucocorticoids (GCs) could benefit from early but temporary etanercept introduction as a second remission-induction attempt. METHODS: CareRA2020 (NCT03649061) was a 2-year, open-label, multicentre, pragmatic randomised controlled trial. Treatment-naïve patients started MTX and GC bridging (COBRA-Slim: CS). Within a time window from week (W) 8 until W32, early insufficient responders (28-joint Disease Activity Score - C-reactive Protein (DAS28-CRP) >3.2 between W8 and W32 or ≥2.6 at W32) were randomised to a Standard-CS strategy (adding leflunomide first) or Bio-induction-CS strategy (adding etanercept for 24 weeks). Additional treatment adaptations followed the treat-to-target principle. Longitudinal disease activity (DAS28-CRP) over 104 weeks (primary outcome), achievement of DAS28-CRP <2.6 28 weeks after randomisation, and biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) use at W104 were compared between randomisation groups. RESULTS: Following CS treatment, 142 patients were early responders; 55 early insufficient responders received Standard-CS and 55 Bio-induction-CS. Superiority of Bio-induction-CS over Standard-CS could not be demonstrated (ß=-0.204, (95% CI -0.486 to 0.078), p=0.157) for the primary outcome. More patients on Bio-induction-CS achieved DAS28-CRP <2.6 at 28 weeks after randomisation (59% (95% CI 44% to 72%) vs 44% (95% CI 31% to 59%) in Standard-CS) and they were treated less frequently with b/tsDMARDs at W104 (19/55, 35%) compared with Standard-CS (29/55, 53%). CONCLUSION: Half of the patients responded well to initial COBRA-Slim induction therapy. In early insufficient responders, adding etanercept for 6 months did not improve disease control over 104 weeks versus adding leflunomide first. However, temporary introduction of etanercept resulted in improved disease control early after randomisation and less patients on b/tsDMARDs at W104. TRIAL REGISTRATION NUMBER: NCT03649061. CTR PILOT APPROVAL BELGIUM: S59474, EudraCT number: 2017-004054-41.
引用
- Bertrand D, Joly J, Neerinckx B, et al. Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial. RMD Open. 2024. PMID: 39117445. doi:10.1136/rmdopen-2024-004535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。